Navigation Links
Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Date:8/13/2008

SAN MATEO, Calif., Aug. 13 /PRNewswire/ -- Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the completion of a $19 Million equity financing. New investors Caxton Advantage Life Sciences Fund (New York, NY) and HBM BioCapital (Cayman Islands) led the financing, and Rachel Leheny, Ph.D. Managing Director of Caxton Advantage Venture Partners (the General Partner of Caxton Advantage Life Sciences Fund) will join Anthera's Board of Directors. The financing also included existing investors VantagePoint Venture Partners, Sofinnova Ventures, Pappas Ventures and Mitsubishi International Corporation.

In addition, the company announced the appointment of Christopher S. Henney as Chairman of the Board. Dr. Henney has served as an independent director of Anthera since 2006. Dr. Henney is a co-founder of three major publicly held U.S. biotechnology companies: Immunex‚ ICOS and Dendreon‚ and has been associated with the formation of several others. Most recently Dr. Henney has served as Chairman and Chief Executive Officer of Dendreon (Nasdaq: DNDN) and as Chairman of SGX Pharmaceuticals (Nasdaq: SGXP) and of Oncothyreon (Nasdaq: ONTY).

"We are delighted to have Caxton Advantage and HBM, two premier health care funds, lead
'/>"/>

SOURCE Anthera Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... First patients dosed with PSX1002, ... designed using Prosonix, particle engineering platform Prosonix, ... inhaled Respiratory Medicines by Design , has initiated ... assess its effect on lung function and the safety ... to severe chronic obstructive pulmonary disease (COPD). The first ...
(Date:5/21/2013)... -- The Lindsley F. Kimball Research Institute of the New York ... Challenges Explorations winner, an initiative funded by the ... Lustigman , Head of the Laboratory of Molecular Parasitology ... titled Innovative 3-D in vitro culturing system ... drugs to help eliminate onchocerciasis (river blindness) in ...
(Date:5/21/2013)... 2013 Through science fairs, workshops, kits ... lab equipment, 25 organizations will continue their work to ... and photonics in daily life with the aid of ... located in 10 countries, are the first of two ... SPIE, the international society for optics and photonics ...
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... for the 13th consecutive year at the Association ... Conference and Expo. The conference brings together professionals ... technologies. This year’s event will be held from ... The three-day event draws over 1,500 healthcare technology ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2
... Instructors at Madison Area Technical College would ... ,Over the last decade, the percentage of women in IT careers ... said Janet Kelly, communications director for MATC. And at MATC, enrollment ... , ,Speaking at the Women in IT Expo at ...
... Milwaukee, Wis . - As part of a new ... new destinations, Midwest Airlines has announced the ... Raleigh/Durham, N.C., the airport that serves Research Triangle ... has been fending off a hostile takeover bid by ...
... Lucigen Corp . and Imaxio S.A. ... worldwide rights to manufacture and sell OverExpress ... agreement, Imaxio will retain the right to license the ... will provide the cells to commercial licensees. No license ...
Cached Biology Technology:MATC seeks to turn around falling tech enrollment among women 2Lucigen Corp. enters global licensing agreement 2
(Date:5/20/2013)... - A National Science Foundation (NSF) planning grant will ... (CARD), a joint program of the University of Illinois ... Mass. , "CARD will be devoted to research in ... agricultural products; forestry and paper products; chemical products; textiles; ... professor of food science and human nutrition and the ...
(Date:5/19/2013)... of electricity-producing bacteria that can grow using hydrogen gas ... its sole source of carbon. Researchers at the ... 113th General Meeting of the American Society for Microbiology. ... solely on hydrogen," says Amit Kumar, a researcher on ... of the Lovley Lab Group at the university. , ...
(Date:5/18/2013)... FL (May 18, 2013) An increasing number ... require interventions to resolve, according to research presented ... one study targeting obesity, researchers at the Cleveland ... a unique pattern of exhaled breath compared to ... volatile organic compound levels that can be correlated ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3
... illustrating the apparent linkages between the evolutionary development and ... elements that determine the structure and function of a ... fish. In addition, they've shown that increasing expression of ... physical changes in the adult fish. The results appear ...
... Institute at Columbia University have discovered that one of ... is actually two genetically distinct groups. The results of ... the journal Animal Conservation, could have far-reaching implications in ... other species on the Subcontinent. , Prithiviraj Fernando, a ...
... therapy according to the individual, and prevent breast cancer ... a study published in the journal Breast Cancer Research, ... of64 genes that can be used to predict a ... for breast cancer. Identifying patients whose breast tumours express ...
Cached Biology News:Changes to embryos can elicit change in adult fish 2Genetic analysis of Asian elephants in India reveals some surprises 2Microarray technology for tailoring breast cancer therapy 2
...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
CKB Antibody (N-term) Antigen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected within aa 1~100 of human CKB. Molecular Weight: 42644 Da...
384 Cluster Tube Racks...
Biology Products: